ReviewCurrent opinion in HIV and AIDS2026
Use of dual ART in individuals with different HBV serological patterns.
Review in Current opinion in HIV and AIDS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTwo-drug regimens (2DR) for antiretroviral therapy are increasingly being recommended for people living with HIV to reduce pill burden and reduce short and long-term toxicity. The exclusion of tenofovir and lamivudine or emtricitabine has implications for acquisition of and reactivation of hepatitis B. RECENT
findingsA number of case-series, cohort studies and randomized-controlled trials of 2Drs have reported on the risk of HBV acquisition and HBV-reactivation (HBVr). The risk of HBVr appears negligible in those switching to 2DRs containing lamivudine, and overall low (~1%) in those switching to tenofovir and lamivudine/emtricitabine-free therapy. Even remote HBsAg positivity is associated with a significant risk of HBVr. SUMMARY: For people with HIV switching to 2DRs careful attention needs to be paid to preswitch HBV serological patterns. For those without previous exposure, and absence of HBsAb, vaccination is important. The risk of HBVr of switching to lamivudine-containing regimens is negligible, and low without tenofovir and lamivudine/emtricitabine. Careful monitoring and preswitch counselling is advised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.